Partners Eli Loots, Ph.D. and Mike Fuller were interviewed for the article “Biosimilars could follow route of authorised generics though technical, market hurdles draw timeline uncertainty” in BioPharm Insight.
Read the full article on the BioPharm Insight website >> (Subscription required)
Subscribe for News and Updates
